carnitine has been researched along with Amyotrophic Lateral Sclerosis in 7 studies
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The relationship between reserve of L-carnitine and severity in patients with Amyotrophic lateral sclerosis (ALS) is not studied sufficiently." | 8.02 | The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis. ( Abaj, F; Asl Motallebnejad, Z; Bitarafan, S; Fathi, D; Nafissi, S; Sarraf, P; Teimouri, R; Vahedi, K, 2021) |
| "The relationship between reserve of L-carnitine and severity in patients with Amyotrophic lateral sclerosis (ALS) is not studied sufficiently." | 4.02 | The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis. ( Abaj, F; Asl Motallebnejad, Z; Bitarafan, S; Fathi, D; Nafissi, S; Sarraf, P; Teimouri, R; Vahedi, K, 2021) |
| "The carnitine concentration was significantly higher in patients than in their spouses, while there were no significant differences in the concentrations of other metabolites." | 1.56 | Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis. ( Chen, L; Chen, Y; Fan, D; Zhao, M; Zheng, L, 2020) |
| "L-carnitine treatment increased the mitochondrial enzyme activities in cortical regions towards control value and was effective in enhancing QO2 and decreasing TBARS levels in the spinal cord of mndT." | 1.31 | Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system. ( Bertamini, M; Bigini, P; Curti, D; Guarneri, P; Guarneri, R; Marzani, B; Mennini, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Goutman, SA | 1 |
| Boss, J | 1 |
| Guo, K | 1 |
| Alakwaa, FM | 1 |
| Patterson, A | 1 |
| Kim, S | 1 |
| Savelieff, MG | 1 |
| Hur, J | 1 |
| Feldman, EL | 1 |
| Chen, L | 1 |
| Chen, Y | 1 |
| Zhao, M | 1 |
| Zheng, L | 1 |
| Fan, D | 1 |
| Sarraf, P | 1 |
| Bitarafan, S | 1 |
| Nafissi, S | 1 |
| Fathi, D | 1 |
| Abaj, F | 1 |
| Asl Motallebnejad, Z | 1 |
| Teimouri, R | 1 |
| Vahedi, K | 1 |
| Bertamini, M | 1 |
| Marzani, B | 1 |
| Guarneri, R | 1 |
| Guarneri, P | 1 |
| Bigini, P | 1 |
| Mennini, T | 1 |
| Curti, D | 1 |
| Kira, Y | 1 |
| Nishikawa, M | 1 |
| Ochi, A | 1 |
| Sato, E | 1 |
| Inoue, M | 1 |
| Sanjak, M | 1 |
| Paulson, D | 1 |
| Sufit, R | 1 |
| Reddan, W | 1 |
| Beaulieu, D | 1 |
| Erickson, L | 1 |
| Shug, A | 1 |
| Brooks, BR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Moderate Aerobic Exercise as Determined by Cardiopulmonary Exercise Testing in ALS[NCT03326622] | 48 participants (Actual) | Interventional | 2013-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for carnitine and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
ALSUntangled 53: Carnitine supplements.
Topics: Amyotrophic Lateral Sclerosis; Carnitine; Dietary Supplements; Humans | 2020 |
Untargeted metabolomics yields insight into ALS disease mechanisms.
Topics: Aged; Amyotrophic Lateral Sclerosis; Benzoates; Carnitine; Case-Control Studies; Ceramides; Creatine | 2020 |
Changes in the concentrations of trimethylamine N-oxide (TMAO) and its precursors in patients with amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Betaine; Carnitine; Choline; Female; Gastrointestinal Microbiome; Hum | 2020 |
The correlation of the serum level of L-carnitine with disease severity in patients with Amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Biomarkers; Body Mass Index; Carnitine; Cross-Sectional | 2021 |
Mitochondrial oxidative metabolism in motor neuron degeneration (mnd) mouse central nervous system.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Carnitine; Central Nervous System; Cerebral Cor | 2002 |
L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis.
Topics: Adenine; Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Carnitine; Disease Progression; Female; | 2006 |
Physiologic and metabolic response to progressive and prolonged exercise in amyotrophic lateral sclerosis.
Topics: 3-Hydroxybutyric Acid; Amyotrophic Lateral Sclerosis; Carnitine; Exercise Test; Fatty Acids, Noneste | 1987 |